[go: up one dir, main page]

NO20064792L - Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom. - Google Patents

Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.

Info

Publication number
NO20064792L
NO20064792L NO20064792A NO20064792A NO20064792L NO 20064792 L NO20064792 L NO 20064792L NO 20064792 A NO20064792 A NO 20064792A NO 20064792 A NO20064792 A NO 20064792A NO 20064792 L NO20064792 L NO 20064792L
Authority
NO
Norway
Prior art keywords
rotigotine
parkinson
treatment
connection
plus syndrome
Prior art date
Application number
NO20064792A
Other languages
English (en)
Inventor
Dieter Scheller
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20064792L publication Critical patent/NO20064792L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen angår anvendelse av rotigotin, dens salter og promedikamenter som et medikament til å forhindre og/eller behandle Parkinsons pluss syndrom.
NO20064792A 2004-03-24 2006-10-23 Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom. NO20064792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004014841A DE102004014841B4 (de) 2004-03-24 2004-03-24 Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
PCT/EP2005/003013 WO2005092331A1 (de) 2004-03-24 2005-03-22 Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms

Publications (1)

Publication Number Publication Date
NO20064792L true NO20064792L (no) 2006-10-23

Family

ID=34963175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064792A NO20064792L (no) 2004-03-24 2006-10-23 Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.

Country Status (17)

Country Link
US (1) US7872041B2 (no)
EP (1) EP1727539B1 (no)
JP (1) JP4801042B2 (no)
KR (1) KR101140452B1 (no)
CN (1) CN100581542C (no)
AT (1) ATE376828T1 (no)
AU (1) AU2005226911B2 (no)
CA (1) CA2559683C (no)
DE (2) DE102004014841B4 (no)
EA (1) EA011278B1 (no)
ES (1) ES2296156T3 (no)
HK (1) HK1100765A1 (no)
MX (1) MXPA06010747A (no)
NO (1) NO20064792L (no)
NZ (1) NZ550025A (no)
UA (1) UA85583C2 (no)
WO (1) WO2005092331A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US8505540B2 (en) 2007-11-13 2013-08-13 Apnicure, Inc. Methods and systems for improving airway patency
SI2215072T1 (sl) 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DK2515887T3 (en) 2009-12-22 2018-09-17 Ucb Biopharma Sprl Polyvinylpyrrolidone to stabilize a solid dispersion of the non-crystalline form of rotigotine
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
MX2012013818A (es) 2010-06-25 2013-01-24 Ucb Pharma Gmbh Procesos para la resolucion de derivados de (s)-5-alcoxi-2-amino-t etralina sustituida con nitrogeno.
US8979823B2 (en) 2011-02-09 2015-03-17 Apnicure, Inc. Saliva management system with continuous flow through oral device
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
EP3145504B1 (en) 2014-05-20 2023-07-26 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas
FR3106978B1 (fr) 2020-02-11 2024-04-26 Olivier Petitjean Utilisation d'une molecule inhibitrice de la production de ros d'origine mitochondriale telle que l'anethole trithione pour traiter la maladie de parkinson

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649300A5 (de) * 1981-08-07 1985-05-15 Sandoz Ag Ergopeptinderivate, ihre herstellung und verwendung.
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
DE3479314D1 (en) * 1984-05-22 1989-09-14 Nelson Res & Dev Substituted 2-aminotetralins and processes for synthesis
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
ES2032570T3 (es) * 1987-11-20 1993-02-16 Farmitalia Carlo Erba S.R.L. Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
DE3827561C1 (no) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
ES2123500T3 (es) * 1989-05-31 1999-01-16 Upjohn Co Derivados de 8-heterociclil-2-aminotetralina activos sobre el sistema nervioso central.
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
SE9301732D0 (sv) 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
TW280819B (no) * 1993-11-17 1996-07-11 Sumitomo Pharma
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
IT1276522B1 (it) 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6010877A (en) * 1997-01-10 2000-01-04 Smithkline Beecham Corporation cDNA clone HE8CS41 that encodes a novel 7-transmembrane receptor
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US6242572B1 (en) 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
IT1292155B1 (it) * 1997-06-13 1999-01-25 Zambon Spa Derivati naftotiazolonici attivi sul recettore dopaminergico d 3
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
AU765142B2 (en) * 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
JP2002519702A (ja) 1998-07-03 2002-07-02 イノジェネティックス・ナムローゼ・フェンノートシャップ 神経変性の分別診断
GB9815618D0 (en) 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
CO5111024A1 (es) 1998-12-29 2001-12-26 Kimberly Clark Co Composiciones de recubrimientos de polimero disparado por ion sobre peliculas de polimero sensibles al agua
EP1232152B1 (en) * 1999-11-23 2004-02-04 Aderis Pharmaceuticals, Inc. Improved process for preparing nitrogen-substituted aminotetralins
US20020110585A1 (en) 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6227875B1 (en) * 1999-12-27 2001-05-08 Hon Hai Precision Ind. Co., Ltd. Connector assembly for vertically mounted hard disk drive
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1332363A4 (en) 2000-10-09 2007-08-29 Kay Double PROOF OF NEURODEGENERATIVE DISEASES
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
EP1344522A1 (en) * 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
AU2002319615A1 (en) 2001-07-20 2003-03-03 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
FR2828212B1 (fr) 2001-08-03 2003-10-31 Aventis Pharma Sa Methodes de diagnostic et de pronostic de la maladie de parkinson
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
KR20100056569A (ko) * 2002-01-28 2010-05-27 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
AU2002339230A1 (en) 2002-03-08 2003-09-22 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
ES2239196T3 (es) 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE502005003491D1 (de) 2004-08-02 2008-05-08 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
EP1796610A4 (en) 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
SI2215072T1 (sl) * 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina

Also Published As

Publication number Publication date
KR20060130730A (ko) 2006-12-19
JP2007530484A (ja) 2007-11-01
KR101140452B1 (ko) 2012-04-30
CN100581542C (zh) 2010-01-20
CA2559683A1 (en) 2005-10-06
CN1960724A (zh) 2007-05-09
NZ550025A (en) 2010-07-30
US7872041B2 (en) 2011-01-18
EA200601746A1 (ru) 2007-04-27
DE102004014841B4 (de) 2006-07-06
AU2005226911B2 (en) 2011-02-10
WO2005092331A1 (de) 2005-10-06
EP1727539A1 (de) 2006-12-06
DE102004014841A1 (de) 2005-10-13
JP4801042B2 (ja) 2011-10-26
ES2296156T3 (es) 2008-04-16
HK1100765A1 (en) 2007-09-28
UA85583C2 (ru) 2009-02-10
MXPA06010747A (es) 2006-12-15
US20070191470A1 (en) 2007-08-16
EA011278B1 (ru) 2009-02-27
AU2005226911A1 (en) 2005-10-06
DE502005001828D1 (de) 2007-12-13
ATE376828T1 (de) 2007-11-15
EP1727539B1 (de) 2007-10-31
CA2559683C (en) 2012-07-17

Similar Documents

Publication Publication Date Title
NO20064792L (no) Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
ATE534378T1 (de) Titrierung von tapentadol
HK1125040A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
MX2010006823A (es) Metodos para el tratamiento de la gota.
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
HK1141231A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
TW200602324A (en) Tetrahydro-indazole cannabinoid modulators cross reference to related applications
UA96592C2 (uk) Індолопіридини як модулятори кінезину eg5
DK1919466T3 (da) Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
ATE540690T1 (de) Insulinkombinationen
WO2008090287A3 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida
NO20076405L (no) Anvendelse av 24-nor-UDCA
MX2009004770A (es) Compuestos de carbamato para usarse en el tratamiento de la depresion.
MX2007006082A (es) Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
UA85187C2 (en) 2-aminobenzoyl derivatives
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
MX2007007183A (es) Aminas, combinacion de aminas y vanadio y sales de amina y vanadio para el tratamiento o prevencion de dislipidemia.
EA201000738A1 (ru) Медицинское применение 3-(2,2,2-триметилгидразиниум)пропионат гидрофумарата и дигидрофосфата
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
EA200801023A1 (ru) Применение фенофибрата или его производного для предотвращения диабетической ретинопатии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application